CAJ | 학술논문

目的：观察氟伐他汀缓释片对原发性高血压(EH)患者血清高敏 C 反应蛋白(hsCRP)、抵抗素及颈动脉内中膜厚度(IMT)的影响和意义。方法将212例 EH 患者随机分为两组,氟伐他汀组(n =107)和对照组(n =105)；两组均给予常规降压治疗,氟伐他汀组在此基础上给予氟伐他汀缓释片80 mg/d,连续口服12周。观察治疗前后低密度脂蛋白胆固醇(LDL-C)、hsCRP、抵抗素水平和 IMT 的变化。结果与治疗前比较,氟伐他汀组在治疗后LDL-C、hsCRP 、抵抗素、IMT 均显著下降,分别为 LDL-C(2.7±0.7)mmol/L vs (1.9±0.6)mmol/L 、hsCRP(5.5±0.8)mg/L vs (2.4±0.9)mg/L、抵抗素(2.7±0.8)μg/L vs (1.7±0.5)μg/L、IMT(2.2±0.3)分 vs (1.4±0.4))分(均 P <0.05)；对照组在治疗后 hsCRP 显著下降,hsCRP(3.7±0.4)mg/L vs (3.9±0.9)mg/L(P <0.05)。治疗12周后,氟伐他汀组 LDL-C、hsCRP、抵抗素、IMT 与对照组比较差异有统计学意义,分别 LDL-C(1.9±0.6) mmol/L vs (2.7±0.5)mmol/L 、hsCRP(2.4±0.9)mg/L vs (3.9±0.9)mg/L、抵抗素(1.7±0.5)μg/L vs (3.2±0.5)μg/L、IMT(1.4±0.4)分 vs (2.2±0.4)分(P <0.05或<0.01)。结论氟伐他汀可改善原发性高血压患者动脉粥样硬化程度,其机制与降低血清 LDL-C、hsCRP、抵抗素水平有关。
목적：관찰불벌타정완석편대원발성고혈압(EH)환자혈청고민 C 반응단백(hsCRP)、저항소급경동맥내중막후도(IMT)적영향화의의。방법장212례 EH 환자수궤분위량조,불벌타정조(n =107)화대조조(n =105)；량조균급여상규강압치료,불벌타정조재차기출상급여불벌타정완석편80 mg/d,련속구복12주。관찰치료전후저밀도지단백담고순(LDL-C)、hsCRP、저항소수평화 IMT 적변화。결과여치료전비교,불벌타정조재치료후LDL-C、hsCRP 、저항소、IMT 균현저하강,분별위 LDL-C(2.7±0.7)mmol/L vs (1.9±0.6)mmol/L 、hsCRP(5.5±0.8)mg/L vs (2.4±0.9)mg/L、저항소(2.7±0.8)μg/L vs (1.7±0.5)μg/L、IMT(2.2±0.3)분 vs (1.4±0.4))분(균 P <0.05)；대조조재치료후 hsCRP 현저하강,hsCRP(3.7±0.4)mg/L vs (3.9±0.9)mg/L(P <0.05)。치료12주후,불벌타정조 LDL-C、hsCRP、저항소、IMT 여대조조비교차이유통계학의의,분별 LDL-C(1.9±0.6) mmol/L vs (2.7±0.5)mmol/L 、hsCRP(2.4±0.9)mg/L vs (3.9±0.9)mg/L、저항소(1.7±0.5)μg/L vs (3.2±0.5)μg/L、IMT(1.4±0.4)분 vs (2.2±0.4)분(P <0.05혹<0.01)。결론불벌타정가개선원발성고혈압환자동맥죽양경화정도,기궤제여강저혈청 LDL-C、hsCRP、저항소수평유관。
Objective To observe the effect and significance of fluvastatin on high sensitive C reactive protein (hsCRP),resistin and intima-media thickness inflammation (IMT)in patients with essential hypertension (EH ). Methods 212 EH patients were randomly divided into two groups:fluvastatin group(n =107)and control group(n =105).Patients in control group and fluvastatin group were given conventional medicine treatment.Patients in fluvastatin group were given orally fluvastatin(80 mg/d)for twelve weeks besides conventional medicine treatment.Low density lipoprotein-cholesterol(LDL-C),hsCRP,resistin and IMT were evaluated in all patients before and after treatment. Results Compared to those before treatment,LDL-C,hsCRP,resistin,IMT decreased after treatment in fluvastatin group,LDL-C(2.7±0.7)mmol/L vs (1.9±0.6)mmol/L,hsCRP(5.5±0.8)mg/L vs (2.4±0.9)mg/L,resistin(2.7± 0.8)μg/L vs (1.7±0.5)μg/L,IMT(2.2 ±0.3)scores vs (1.4 ±0.4)scores(all P <0.05 );hsCRP decreased after treatment in the control group,hsCRP(3.7 ± 0.4)mg/L vs (3.9 ± 0.9 )mg/L(P < 0.05 ).After treatment for 12 weeks,LDL-C,hsCRP,resistin,IMT in fluvastatin group were significantly different compared with those in control group,LDL-C(1.9±0.6)mmol/L vs (2.7 ±0.5)mmol/L,hsCRP(2.4 ±0.9)mg/L vs (3.9 ±0.9)mg/L,resistin (1.7±0.5 )μg/L vs (3.2 ± 0.5 )μg/L,IMT(1.4 ± 0.4)scores vs (2.2 ± 0.4)scores (P < 0.01 ).Conclusion Fluvastatin can improve atherosclerosis by decreasing LDL-C,hsCRP and resistin.